Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer

You may be eligible if

• Required Characteristics:
• 1. Adult post menopausal women or women with no childbearing potential (≥ 18 years) with a history of breast cancer (currently no evidence of disease) or women who do not want to take vaginal estrogen for a fear of an increased risk of breast cancer. Postmenopausal status will be determined by the primary physician.
• 2. Significant vaginal complaints defined as persistent vaginal dryness and/or itching of sufficient severity to make a patient desire therapeutic intervention. Symptoms should have been present ≥ 2 months prior to randomization.
• 3. Life expectancy \> 6 months
• 4. Ability to complete questionnaire(s) by themselves or with assistance.
• Contraindications:
• 1. Initiation or discontinuation of tamoxifen or aromatase inhibitors ≤2 months prior to randomization or plans to initiate or discontinue any of these medications during the 6-week study.
• 2. Active vaginal infection
• 3. Concurrent chemotherapy
• 4. Acute iritis
• 5. Current or past use of pilocarpine (regardless of purpose)
• 6. Planned use of any vaginal preparations during the study period (including any over the counter or herbal preparations). Note: Lubricants used during sexual intercourse are permitted.
• 7. Use of any vaginal preparations ≤ 1 week prior to study entry (Exception: If patient has used vaginal preparations during the previous week but will stop, then they can be placed on study with plans to start with pretreatment questionnaire one week later). Note: Lubricants used during sexual intercourse are permitted.
• 8. Current (≤ 4weeks prior to randomization), or planned during the study period, use of any estrogen product.
• 9. A diagnosis of asthma, COPD, CAD or narrow angle glaucoma, or known cholelithiasis.
• 10. Hepatic or renal insufficiency defined as a history of an elevation of SGOT ≥1.5 x ULN or creatinine ≥ 1.5 x ULN within the past year.
• 11. Concurrent use of other anticholinergics
• 12. Use of pharmacologic soy preparations
• 13. Known history of cardiac arrhythmia. (Patients with occasional PVC's or PAC's that do not require treatment are eligible.)
• 14. Prior or concurrent pelvic radiation therapy
• 15. Prior radical pelvic surgery (TAH/BSO is allowed)
• 16. Use of beta adrenergic antagonists
• 17. Diagnosis of any of the following conditions:
• * Vulvar and vaginal dysplasia
• * Essential vulvodynia
• * Vulvar vestibulitis
• * Vaginal prolapse
• * Bartholin cyst/abscess
• * History of Bartholin gland surgery
• * Lichen sclerosis
• * Lichen planus of the vulvovaginal region
• * Desquamative vaginitis